Holothuria scabra extracts exhibit anti-Parkinson potential in C. elegans: A model for anti-Parkinson testing

Parkinson's disease (PD) is associated with aggregation of α-synuclein and selective death of dopaminergic (DA) neurons in the substantia nigra, thereby leading to cognitive and motor impairments. Nowadays, the drugs commonly used for PD treatment, such as levodopa, provide only symptomatic relief. Therefore, seeking new drugs against PD, especially from plants and marine organisms, is one of the major research areas to be explored. This study aimed to investigate the anti-Parkinson activity of the extracts from the sea cucumber, Holothuria scabra, by using Caenorhabditis elegans as a model.

H. scabra was solvent-extracted and subdivided into six fractions including whole body-ethyl acetate (WBEA), body wall-ethyl acetate (BWEA), viscera-ethyl acetate (VIEA), whole body-butanol (WBBU), body wall-butanol (BWBU), and viscera-butanol (VIBU). The extracts were tested in C. elegans BZ555 strain expressing the green fluorescent protein (GFP) specifically in the DA neurons and NL5901 strain expressing human α-synuclein in the muscle cells.

WBEA, BWEA, and WBBU fractions of H. scabra extracts at 500 µg/ml significantly attenuated DA neuron-degeneration induced by selective cathecholamine neurotoxin 6-hydroxydopamine (6-OHDA) in the BZ555 strain. Moreover, the extracts also reduced α-synuclein aggregation and restored lipid content in NL5901, as well as improved food-sensing behavior and prolonged lifespan in the 6-OHDA-treated wild-type strain.

The study indicated that the H. scabra extracts have anti-Parkinson potential in the C. elegans model. These findings encourage further investigations on using the H. scabra extract, as well as its active constituent compounds, as a possible preventive and/or therapeutic intervention against PD.